Multidistrict Litigation (MDL) Explained: Consolidation of Federal Injury Cases
Multidistrict litigation is a federal procedural mechanism that consolidates civil cases sharing common factual questions from multiple districts into a single court for coordinated pretrial proceedings. The governing statute, 28 U.S.C. § 1407, authorizes this consolidation to eliminate duplicative discovery, prevent inconsistent pretrial rulings, and conserve judicial resources across the federal court system. MDL proceedings affect tens of thousands of plaintiffs annually and have shaped outcomes in mass pharmaceutical, medical device, and product liability litigation at a scale no single district court could manage alone.
Definition and scope
Multidistrict litigation is created under 28 U.S.C. § 1407, enacted in 1968, which established the Judicial Panel on Multidistrict Litigation (JPML). The JPML is a seven-judge body drawn from the federal judiciary whose sole function is to evaluate transfer petitions and assign consolidated dockets to a single transferee district. The panel publishes its transfer orders and statistics through the United States Courts system.
MDL applies only to civil federal actions — it has no criminal counterpart. Consolidation is limited to pretrial proceedings. Once pretrial activity concludes, individual cases that have not settled are remanded to their original districts for trial under 28 U.S.C. § 1407(a). This distinguishes MDL from class action lawsuits, where a single certified class proceeding can proceed through trial and bind all members. In MDL, each plaintiff retains an individual claim with individual damages — the consolidation is procedural, not substantive.
As of the JPML's 2023 statistical report, MDL dockets accounted for approximately 70% of all pending federal civil cases at certain peak periods, with product liability matters comprising the largest single category of active MDL dockets.
How it works
The MDL process follows a defined sequence of phases governed by § 1407 and JPML Rules of Procedure (Rules of the JPML):
-
Petition for transfer. Any party in any related federal action may file a motion to transfer with the JPML. The petition must demonstrate that the actions share "one or more common questions of fact" and that transfer will serve the convenience of parties and witnesses and promote just and efficient conduct.
-
Hearing and panel determination. The JPML schedules a hearing session, receives written submissions from parties in all related actions, and issues a transfer order if the statutory criteria are met. Transfer can also occur sua sponte — initiated by the panel without a party petition.
-
Selection of transferee district and judge. The JPML selects both the receiving district and, typically, a specific district judge with demonstrated capacity to manage complex litigation. The assigned judge is called the transferee judge or MDL judge.
-
Appointment of leadership structure. The transferee judge appoints a Plaintiffs' Steering Committee (PSC) and often a Lead Counsel to coordinate discovery and motion practice on behalf of all plaintiffs. Defense counsel are similarly organized.
-
Coordinated pretrial proceedings. The MDL docket undergoes consolidated discovery, including document production, depositions, and expert witness designation. The Daubert standard for expert admissibility is litigated at this stage and applies across all constituent cases.
-
Bellwether trials. In most large MDLs, the transferee judge selects a small number of representative cases — typically 3 to 10 — for trial. These bellwether verdicts provide data on damages exposure and often catalyze global settlement negotiations without requiring individual trials for every plaintiff.
-
Resolution and remand. Cases resolve through individual settlements, global settlement funds, or, where no settlement is reached, remand to the originating district for trial. The JPML formally remands under § 1407(a) upon pretrial completion.
Common scenarios
MDL consolidation appears most frequently in five categories of federal civil litigation:
Pharmaceutical and drug injury. Consolidated cases alleging harm from a single drug or drug class — such as opioid litigation or anticoagulant drug litigation — form a dominant MDL category. The underlying tort law claims typically sound in product liability, failure to warn, and negligence.
Medical device defect. Hip replacement systems, hernia mesh products, and implantable cardiac devices have generated some of the largest MDL dockets in JPML history. These cases involve both strict liability manufacturing defect claims and design defect allegations.
Consumer products and environmental exposure. Mass tort claims tied to chemical exposure, contaminated water systems, or defective consumer goods are consolidated when plaintiffs from multiple states file in federal courts based on diversity or federal question jurisdiction.
Aviation and transportation disasters. Multi-plaintiff cases arising from a single crash or systemic safety failure often meet the § 1407 commonality standard quickly given the shared factual record of a discrete event.
Securities and financial injury. Although distinct from personal injury, MDL also governs coordinated securities fraud and ERISA breach actions, demonstrating the mechanism's breadth beyond physical harm claims.
MDL differs structurally from mass tort litigation as a general category. Mass tort is a substantive description of litigation involving large numbers of plaintiffs harmed by a common product or event; MDL is the procedural vehicle that federal courts use to manage such litigation. A mass tort may proceed in state court without any MDL designation, and an MDL docket may encompass claims that would not classically be described as mass torts.
Decision boundaries
Several thresholds and distinctions determine whether § 1407 consolidation applies and how it interacts with related doctrines.
MDL versus class certification. Class actions under Federal Rule of Civil Procedure 23 require that common questions predominate and that a class representative adequately represents all members. MDL requires only shared factual questions — a far lower threshold. Class certification binds non-consenting members through a final judgment; MDL does not. Plaintiffs in an MDL retain individual claims and can, in principle, opt for individual trial upon remand.
Venue and jurisdiction prerequisites. For a case to enter an MDL docket, it must already be properly filed in federal district court. Venue and jurisdiction rules must be satisfied independently; § 1407 transfer does not cure a jurisdictional defect. Diversity jurisdiction under 28 U.S.C. § 1332 or federal question jurisdiction under 28 U.S.C. § 1331 must be established before transfer.
Choice of law complexity. The transferee court applies the substantive law of each plaintiff's originating jurisdiction for that plaintiff's individual claims. Choice of law in multistate injury cases remains a significant source of complexity in MDL, particularly for compensatory damages, damage caps, and statute of limitations questions.
Settlement allocation and liens. Global MDL settlements involve complex allocation structures, frequently administered by court-appointed special masters. Medicare and Medicaid lien resolution, subrogation rights, and lien resolution are mandatory components of any qualifying settlement involving federal healthcare program beneficiaries, governed by the Medicare Secondary Payer Act (42 U.S.C. § 1395y).
Statutes of limitations and tolling. Filing in an MDL does not automatically toll state statutes of limitations. The federal court system applies the discovery rule and tolling doctrines of the originating state. Plaintiffs who file after the applicable limitations period — even if an MDL docket is active — face dismissal on individual grounds regardless of the consolidated proceeding's status.
References
- Judicial Panel on Multidistrict Litigation (JPML) — Official site for transfer orders, docket statistics, and rules of procedure.
- 28 U.S.C. § 1407 — Multidistrict Litigation — Enabling statute for MD